Bevacizumab and other monoclonal antibodies against vascular endothelial growth factor (VEGF) have shown efficacy in combination with chemotherapy, improving progression-free survival in patients with advanced cervical cancer [13, 14]. Here, VEGFA is linked to cervical carcinoma.